To evaluate both whether SHN3 inhibition is a potential therapeutic approach to treat OI and also whether SHN3-mediated regulation of the skeletal vascular microenvironment is relevant to OI phenotypes, we intercrossed Shn3−/− mice with Col1a2oim/oim mice 14. This evidence concerns the gene HIVEP3 and osteogenesis imperfecta.